Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-2012 vs Pegfilgrastim for Neutropenia in Breast Cancer
NCT01724866Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Mar 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of esketamine in neutropenia, sponsored by Spectrum Pharmaceuticals, Inc.. Started Mar 2013; status: completed.
02
Drugs
esketamine
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT01724866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01724866.